Cagrilintide/semaglutide
RENEW 4
Novo Nordisk · Phase 3 · Recruiting · Enrollment 285
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2 | n/r | n/r | n/r | n/r |
| Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1 | n/r | n/r | n/r | n/r |
| Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1 | n/r | n/r | n/r | n/r |
Not shown
- Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2: endpoint not reported
- Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1: endpoint not reported
- Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1: endpoint not reported